News Archives - Page 5 of 87

TuesdaySep 17, 2024 12:07 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Inks Sales, Service Agreement with Leading Commercial Dealer Group

Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, is adding to its EV dealership network. According to the company, premier full-service dealer Papé Kenworth has become Mullen’s seventh franchise dealer partner. Based in Eugene, Oregon, Papé Kenworth, which is part of the Papé Group, has more than 30 locations and is the West's premiere, full-service Kenworth truck dealer. The dealership is partnering with Mullen to provides zero-emissions trucks for a wide range of applications as it supports customers that are adapting to comply with evolving regulations. “Papé Kenworth is a hallmark dealer and distributor with unmatched and deep experience…

FridaySep 13, 2024 1:34 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) to Effect 1-for-100 Reverse Stock Split

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it will implement a 1-for-100 reverse stock split of its common stock, par value $0.001 per share, automatically combining and converting 100 current shares of its common stock into one issued and outstanding share of common stock. The reverse stock split, approved by the company’s stockholders and the board of directors, will take effect on September 17, 2024, at 12:01 a.m. ET. Following the split, the new CUSIP number will be 62526P505, with Mullen’s common stock trading on a split-adjusted basis under the existing ticker symbol MULN.…

FridaySep 06, 2024 9:59 am

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, provided a strategic letter from outgoing CEO Chris Bunka updating all stakeholders. In the strategic update, Bunka discussed Lexaria’s performance in the capital markets; the company’s Phase 1b DehydraTECH-CBD hypertension trial and Australian-registered Phase 1b DehydraTECH-GLP-1 diabetes and weight-loss study; ongoing R&D; and his reason for stepping aside from his role as CEO. “It is because of the combination of events that include our successful money-raising, our R&D success, our new relationship with one pharmaceutical company and continued pursuit of others, and our confidence in our strategic direction…

ThursdaySep 05, 2024 2:31 pm

TinyGemsBreaks – Reliant Coffee Named to the 2024 Inc. 5000 List of Fastest Growing Companies

Reliant Coffee, the leading provider of premium B2B automated bean-to-cup coffee subscription services, is announcing that it has been named to the Inc. 5000 class of 2024, debuting at #271 among all companies. Reliant Coffee was ranked 14th in the Food and Beverage category and 32nd among Florida companies. An exclusive ranking of the country’s fastest-growing private companies, the 2024 Inc. 5000 list represents companies that have posted rapid revenue growth amid inflationary pressure, the rising costs of capital, and hiring challenges. “We are honored to debut at number 271 on the Inc. 5000 list of fastest growing companies,” commented…

ThursdayAug 29, 2024 12:07 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test Results

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting that the tolerability and additional pharmacokinetic (“PK”) results from its human pilot study #2, GLP-1-H24-2, have been received. According to the results, absorption improvements appear to continue with DehydraTECH-processed Rybelsus(R) vs. Rybelsus tablets, even under “fed” conditions. The results also show that DehydraTECH-treated Rybelsus does absorb through a mouth-melt product format. “We were pleased to find that none of the nine people taking the DehydraTECH-processed Rybelsus swallowed as a capsule experienced any adverse events whatsoever,” the company stated in the press release. “However, of the nine human…

TuesdayAug 27, 2024 2:04 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, is announcing receipt of the first results from human pilot study #2, GLP-1-H24-2. According to the announcement, the company’s DehydraTECH(R)-processed Rybelsus(R) evidenced a trend toward higher overall absorption under fed conditions compared to Rybelsus(R) that was not processed with DehydraTECH. The DehydraTECH-processed Rybelsus(R) evidenced higher semaglutide levels in 17 of the 19 blood draws taken until the 24-hour completion of the study, averaging 18.8% higher semaglutide levels over the course of the study compared to Rybelsus(R) alone. However, the announcement noted that the differences were variable and not…

TuesdayAug 27, 2024 1:17 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that CEO John Climaco will present and discuss recent corporate events at the upcoming LIVE! with Webull Corporate Connect: Virtual Biotech Investor Webinar. The presentation is scheduled for Wednesday, August 28, 2024, at 3:20 p.m. ET. To register for the live webinar, visit https://ibn.fm/JXz89 To view the full press release, visit https://ibn.fm/GfqLq About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug…

ThursdayAug 22, 2024 1:03 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, is reporting on 8-week body weight results from its ongoing animal study WEIGHT-A24-1. According to the company, this is the only study carried out anywhere in the world today to evaluate the relative performance of liraglutide processed with DehydraTECH. The results show that DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutide. In humans, semaglutide has been shown in other studies to be more than twice as effective at promoting weight loss as liraglutide. Thus, the announcement noted that the continued outperformance of DehydraTECH-liraglutide compared to DehydraTECH-semaglutide is of particular interest. Additionally, the…

WednesdayAug 21, 2024 11:50 am

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Subsidiary to Begin Production of All-New Class 4 Commercial Truck in September

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that Bollinger Motors, its subsidiary, intends to begin production of saleable units of the Bollinger B4 Chassis Cab, an all-new Class 4 commercial EV truck, on September 16, 2024. Bollinger Motors is partnering on production with Roush Industries, which provides contract manufacturing services from its facility in Livonia, Michigan. According to the announcement, deliveries and revenue recognition of the B4 EV truck is expected to begin in October 2024. “We are already experiencing strong momentum in the market from important customers throughout the country,” commented Jim Connelly, chief…

WednesdayAug 21, 2024 11:25 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Three U.S. Patent Issuances

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates, today announced its receipt of three patents granted in the U.S., strengthening its patent portfolio. The issued patents include one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation. As of August 20, 2024, InMed has a total of 13 patent families covering new chemical entities, formulations, manufacturing processes and methods of use. “We are pleased to…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Breaks Categories: News